Ascendis Pharma A/S (ASND) Financials
ASND Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 912.7 million | 1.1 billion |
2023-09-30 | 924.4 million | 1.0 billion |
2023-06-30 | 895.8 million | 825.3 million |
2023-03-31 | 1.1 billion | 871.0 million |
ASND Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -46.9 million | 17.6 million |
2023-09-30 | -133.1 million | 18.2 million |
2023-06-30 | -167.0 million | 21.6 million |
2023-03-31 | -161.5 million | 14.9 million |
ASND Net Income
No data available :(
ASND Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 441.6 million | - | 109.2 million |
2023-09-30 | 482.1 million | - | 110.7 million |
2023-06-30 | 468.8 million | - | - |
2023-03-31 | 638.5 million | - | - |
ASND Shares Outstanding
ASND Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 69643 | 100.5 million | 70.7 million | - |
2023-09-30 | 1.0 million | 118.0 million | 67.3 million | - |
2023-06-30 | 482776 | 114.2 million | 76.4 million | - |
2023-03-31 | 1.2 million | 115.7 million | 72.5 million | - |
ASND Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 152.2 million | 21.5 million |
2023-09-30 | 50.9 million | 7.8 million |
2023-06-30 | 51.5 million | 14.1 million |
2023-03-31 | 36.6 million | 5.0 million |
ASND
Price: $141.01
52 week price:
Earnings Per Share: -9.19 USD
P/E Ratio: -12.10
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 126716
Ebitda: -36.5 millionMarket Capitalization: 7.7 billion